Lessons from gain- and loss-of-function models of pro-survival Bcl2 family proteins: Implications for targeted therapy

FEBS Journal

Volumn 282, Issue 5, 2015, Pages 834-849

  Sochalska, Maja ^a   Tuzlak, Selma ^a   Egle, Alexander ^b   Villunger, Andreas ^a  

^a INNSBRUCK MEDICAL UNIVERSITY   (Austria)

^b PARACELSUS MEDICAL UNIVERSITY   (Austria)

Author keywords

apoptosis; Bcl 2 family; cancer; mouse models; targeted therapy

Indexed keywords

4 [4 (4' CHLORO 2 BIPHENYLYLMETHYL) 1 PIPERAZINYL] N [4 [3 DIMETHYLAMINO 1 (PHENYLTHIOMETHYL)PROPYLAMINO] 3 NITROBENZENESULFONYL]BENZAMIDE; BCL2 RELATED PROTEIN A1; BH3 PROTEIN; BIM PROTEIN; CASPASE 8; CRE RECOMBINASE; DIETHYLNITROSAMINE; NAVITOCLAX; PROTEIN BAK; PROTEIN BAX; PROTEIN BCL 2; PROTEIN BCL X; PROTEIN MCL 1; PUMA PROTEIN; T LYMPHOCYTE RECEPTOR BETA CHAIN; TAMOXIFEN; VENETOCLAX; BCL2-RELATED PROTEIN A1; BCL2L1 PROTEIN, HUMAN; MCL1 PROTEIN, HUMAN; MYELOID LEUKEMIA FACTOR 1;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; AUTOIMMUNE DISEASE; AUTOIMMUNITY; B LYMPHOCYTE DIFFERENTIATION; BREAST CANCER; CANCER RESISTANCE; CELL DEATH; CELL SURVIVAL; CELLULAR DISTRIBUTION; CELLULAR IMMUNITY; CLINICAL TRIAL (TOPIC); DEVELOPMENTAL DISORDER; DRUG PROTEIN BINDING; DRUG TARGETING; EMBRYO DEVELOPMENT; ENDOMETRIUM HYPERPLASIA; GAIN OF FUNCTION MUTATION; GENE ACTIVATION; GENE DELETION; GENE EXPRESSION REGULATION; GENE FUNCTION; GENE LOCATION; GENE OVEREXPRESSION; GENETIC PREDISPOSITION; GROWTH RETARDATION; HEMATOLOGIC MALIGNANCY; HOMEOSTASIS; HUMAN; IMMUNOSTIMULATION; KIDNEY POLYCYSTIC DISEASE; LIVER CELL CARCINOMA; LOSS OF FUNCTION MUTATION; LYMPHOCYTOPENIA; LYMPHOCYTOPOIESIS; LYMPHOMA; MALIGNANT NEOPLASTIC DISEASE; MELANOMA; NEPHROTOXICITY; NEUROTOXICITY; NEUTROPENIA; NONHUMAN; OUTCOME ASSESSMENT; PHASE 1 CLINICAL TRIAL (TOPIC); PHENOTYPE; PHENOTYPIC VARIATION; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; PROTEIN PROTEIN INTERACTION; PROTO ONCOGENE; QUALITY OF LIFE; REVIEW; SEQUENCE HOMOLOGY; SKIN ALLERGY; SOLID TUMOR; SUNBURN; THROMBOCYTOPENIA; TRANSGENIC MOUSE; ANIMAL; B CELL LYMPHOMA; CHEMISTRY; GENE INACTIVATION; GENETICS; KNOCKOUT MOUSE; METABOLISM; MOLECULARLY TARGETED THERAPY; PATHOLOGY;

MUS;

ANIMALS; BCL-X PROTEIN; CELL SURVIVAL; GENE KNOCKOUT TECHNIQUES; HUMANS; LYMPHOMA, B-CELL; MICE, KNOCKOUT; MICE, TRANSGENIC; MOLECULAR TARGETED THERAPY; MYELOID CELL LEUKEMIA SEQUENCE 1 PROTEIN; PROTO-ONCOGENE PROTEINS C-BCL-2;

EID: 84923856052     PISSN: 1742464X     EISSN: 17424658     Source Type: Journal    
DOI: 10.1111/febs.13188     Document Type: Review

References (120)

1. Czabotar PE, Lessene G, Strasser A, &, Adams JM, (2013) Control of apoptosis by the BCL-2 protein family: implications for physiology and therapy. Nat Rev Mol Cell Biol 15, 49-63.
2. Tait SW, &, Green DR, (2013) Mitochondrial regulation of cell death. Cold Spring Harb Persp Biol 5, 1-12.
3. Strasser A, O'Connor L, Huang DCS, O'Reilly LA, Stanley ML, Bath ML, Adams JM, Cory S, &, Harris AW, (1996) Lessons from bcl-2 transgenic mice for immunology, cancer biology and cell death research. Behring Inst Mitt 97, 101-117.
4. Rinkenberger JL, Horning S, Klocke B, Roth K, &, Korsmeyer SJ, (2000) Mcl-1 deficiency results in peri-implantation embryonic lethality. Genes Dev 14, 23-27.
5. Motoyama N, Wang FP, Roth KA, Sawa H, Nakayama K, Nakayama K, Negishi I, Senju S, Zhang Q, Fujii S, et al,. (1995) Massive cell death of immature hematopoietic cells and neurons in Bcl-x deficient mice. Science (New York, NY) 267, 1506-1510.
6. Ma A, Pena JC, Chang B, Margosian E, Davidson L, Alt FW, &, Thompson CB, (1995) Bclx regulates the survival of double-positive thymocytes. Proc Natl Acad Sci USA 92, 4763-4767.
7. Veis DJ, Sorenson CM, Shutter JR, &, Korsmeyer SJ, (1993) Bcl-2-deficient mice demonstrate fulminant lymphoid apoptosis, polycystic kidneys, and hypopigmented hair. Cell 75, 229-240.
8. Nakayama K-I, Nakayama K, Izumi N, Kulda K, Shinkai Y, Louie MC, Fields LE, Lucas PJ, Stewart V, Alt FW, et al,. (1993) Disappearance of the lymphoid system in Bcl-2 homozygous mutant chimeric mice,. Science (New York, NY) 261, 1584-1588.
9. Kamada S, Shimono A, Shinto Y, Tsujimura T, Takahashi T, Noda T, Kitamura Y, Kondoh H, &, Tsujimoto Y, (1995) bcl-2 deficiency in mice leads to pleiotropic abnormalities: accelerated lymphoid cell death in thymus andspleen, polycystic kidney, hair hypopigmentation, and distorted small intestine. Cancer Res 55, 354-359.
10. Hatakeyama S, Hamasaki A, Negishi I, Loh DY, Sendo F, &, Nakayama K, (1998) Multiple gene duplication and expression of mouse bcl-2-related genes, A1. Int Immunol 10, 631-637.
11. Hamasaki A, Sendo F, Nakayama K, Ishida N, Negishi I, Nakayama K-I, &, Hatakeyama S, (1998) Accelerated neutrophil apoptosis in mice lacking A1-a, a subtype of the bcl-2-related A1 gene. J Exp Med 188, 1985-1992.
12. Print CG, Loveland KL, Gibson L, Meehan T, Stylianou A, Wreford N, de Kretser D, Metcalf D, Köntgen F, Adams JM, et al,. (1998) Apoptosis regulator Bcl-w is essential for spermatogenesis but appears otherwise redundant. Proc Natl Acad Sci USA 95, 12424-12431.
13. Ross AJ, Waymire KG, Moss JE, Parlow AF, Skinner MK, Russell LD, &, MacGregor GR, (1998) Testicular degeneration in Bclw-deficient mice. Nat Genet 18, 251-256.
14. Russell HR, Lee Y, Miller HL, Zhao J, &, McKinnon PJ, (2002) Murine ovarian development is not affected by inactivation of the bcl-2 family member diva. Mol Cell Biol 22, 6866-6870.
15. Green DR, &, Walczak H, (2013) Apoptosis therapy: driving cancers down the road to ruin. Nat Med 19, 131-133.
16. Tsujimoto Y, Finger LR, Yunis J, Nowell PC, &, Croce CM, (1984) Cloning of the chromosome breakpoint of neoplastic B cells with the t(14;18) chromosome translocation. Science (New York, NY) 226, 1097-1099.
17. H on chromosome 14 and near a transcriptional unit on 18. Cell 41, 899-906.
18. McDonnell TJ, Deane N, Platt FM, Nuñez G, Jaeger U, McKearn JP, &, Korsmeyer SJ, (1989) bcl-2-immunoglobulin transgenic mice demonstrate extended B cell survival and follicular lymphoproliferation. Cell 57, 79-88.
19. McDonnell TJ, &, Korsmeyer SJ, (1991) Progression from lymphoid hyperplasia to high-grade malignant lymphoma in mice transgenic for the t(14;18). Nature 349, 254-256.
20. Strasser A, Harris AW, &, Cory S, (1991) Bcl-2 transgene inhibits T cell death and perturbs thymic self-censorship. Cell 67, 889-899.
21. Strasser A, Whittingham S, Vaux DL, Bath ML, Adams JM, Cory S, &, Harris AW, (1991) Enforced BCL2 expression in B-lymphoid cells prolongs antibody responses and elicits autoimmune disease. Proc Natl Acad Sci USA 88, 8661-8665.
22. Strasser A, Harris AW, Bath ML, &, Cory S, (1990) Novel primitive lymphoid tumours induced in transgenic mice by cooperation between myc and bcl-2. Nature 348, 331-333.
23. Ogilvy S, Metcalf D, Print CG, Bath ML, Harris AW, &, Adams JM, (1999) Constitutive bcl-2 expression throughout the hematopoietic compartment affects multiple lineages and enhances progenitor cell survival. Proc Natl Acad Sci USA 96, 14943-14948.
24. Jager R, Herzer U, Schenkel J, &, Weiher H, (1997) Overexpression of Bcl-2 inhibits alveolar cell apoptosis during involution and accelerates c-myc-induced tumorigenesis of the mammary gland in transgenic mice. Oncogene 15, 1787-1795.
25. Li M, Lewis B, Capuco AV, Laucirica R, &, Furth PA, (2000) WAP-TAg transgenic mice and the study of dysregulated cell survival, proliferation, and mutation during breast carcinogenesis. Oncogene 19, 1010-1019.
26. Pierce RH, Vail ME, Ralph L, Campbell JS, &, Fausto N, (2002) Bcl-2 expression inhibits liver carcinogenesis and delays the development of proliferating foci. Am J Pathol 160, 1555-1560.
27. Baumgartner F, &, Villunger A, (2011) Apoptosis: a barrier against cancer no more? Hepatology 54, 1121-1124.
28. Frenzel A, Grespi F, Chmelewskij W, &, Villunger A, (2009) Bcl2 family proteins in carcinogenesis and the treatment of cancer. Apoptosis 14, 584-596.
29. Michaelidis TM, Sendtner M, Cooper JD, Airaksinen MS, Holtmann B, Meyer M, &, Thoenen H, (1996) Inactivation of bcl-2 results in progressive degeneration of motoneurons, sympathetic and sensory neurons during early postnatal development. Neuron 17, 75-89.
30. Manzl C, Baumgartner F, Peintner L, Schuler F, &, Villunger A, (2013) Possible pitfalls investigating cell death responses in genetically engineered mouse models and derived cell lines. Methods 61, 130-137.
31. Matsuzaki Y, Nakayama K-I, Nakayama K, Tomita T, Isoda M, Loh DY, &, Nakauchi H, (1997) Role of bcl-2 in the development of lymphoid cells from the hematopoietic stem cell. Blood 89, 853-862.
32. Villunger A, Scott C, Bouillet P, &, Strasser A, (2003) Essential role for the BH3-only protein Bim but redundant roles for Bax, Bcl-2, and Bcl-w in the control of granulocyte survival. Blood 101, 2393-2400.
33. Pierson W, Cauwe B, Policheni A, Schlenner SM, Franckaert D, Berges J, Humblet-Baron S, Schonefeldt S, Herold MJ, Hildeman D, et al,. (2013) Antiapoptotic Mcl-1 is critical for the survival and niche-filling capacity of Foxp3(+) regulatory T cells. Nat Immunol 14, 959-965.
34. Bouillet P, Cory S, Zhang L-C, Strasser A, &, Adams JM, (2001) Degenerative disorders caused by Bcl-2 deficiency are prevented by loss of its BH3-only antagonist Bim. Dev Cell 1, 645-653.
35. Thorp E, Li Y, Bao L, Yao PM, Kuriakose G, Rong J, Fisher EA, &, Tabas I, (2009) Brief report: increased apoptosis in advanced atherosclerotic lesions of Apoe-/- mice lacking macrophage Bcl-2. Arterioscler Thromb Vasc Biol 29, 169-172.
36. Merino R, Ding L, Veis DJ, Korsmeyer SJ, &, Nuñez G, (1994) Developmental regulation of the Bcl-2 protein and susceptibility to cell death in B lymphocytes. EMBO J 13, 683-691.
37. Grillot DAM, Merino R, Pena JC, Fanslow WC, Finkelman FD, Thompson CB, &, Núñez G, (1996) bcl-x exhibits regulated expression during B cell development and activation and modulates lymphocyte survival in transgenic mice. J Exp Med 183, 381-391.
38. L displays restricted distribution during T cell development and inhibits multiple forms of apoptosis but not clonal deletion in transgenic mice. J Exp Med 182, 1973-1983.
39. Chao DT, Linette GP, Boise LH, White LS, Thompson CB, &, Korsmeyer SJ, (1995) Bcl-x(L) and Bcl-2 repress a common pathway of cell death. J Exp Med 182, 821-828.
40. L transgene. Immunity 4, 291-299.
41. L prevents bacterial superantigen-induced apoptosis of thymocytes in vitro. Cell Death Differ 4, 159-165.
42. L escape negative selection and are tolerized by clonal anergy and receptor editing. Immunity 9, 35-45.
43. L. Proc Natl Acad Sci USA 96, 14871-14876.
44. de La Coste A, Mignon A, Fabre M, Gilbert E, Porteu A, Van Dyke T, Kahn A, &, Perret C, (1999) Paradoxical inhibition of c-myc-induced carcinogenesis by Bcl-2 in transgenic mice. Cancer Res 59, 5017-5022.
45. Rodriguez I, Matsuura K, Khatib K, Reed JC, Nagata S, &, Vassalli P, (1996) A bcl-2 transgene expressed in hepatocytes protects mice from fulminant liver destruction but not from rapid death induced by anti-Fas antibody injection. J Exp Med 183, 1031-1036.
46. Dzhagalov I, Dunkle A, &, He YW, (2008) The anti-apoptotic Bcl-2 family member Mcl-1 promotes T lymphocyte survival at multiple stages. J Immunol 181, 521-528.
47. Malin S, McManus S, Cobaleda C, Novatchkova M, Delogu A, Bouillet P, Strasser A, &, Busslinger M, (2010) Role of STAT5 in controlling cell survival and immunoglobulin gene recombination during pro-B cell development. Nat Immunol 11, 171-179.
48. Vikstrom I, Carotta S, Luthje K, Peperzak V, Jost PJ, Glaser S, Busslinger M, Bouillet P, Strasser A, Nutt SL, et al,. (2011) Mcl-1 is essential for germinal center formation and B cell memory. Science (New York, NY) 330, 1095-1099.
49. Sathe P, Delconte RB, Souza-Fonseca-Guimaraes F, Seillet C, Chopin M, Vandenberg CJ, Rankin LC, Mielke LA, Vikstrom I, Kolesnik TB, et al,. (2014) Innate immunodeficiency following genetic ablation of Mcl1 in natural killer cells. Nat Commun 5, 4539.
50. Wagner KU, Claudio E, Rucker EB, 3rd, Riedlinger G, Broussard C, Schwartzberg PL, Siebenlist U, &, Hennighausen L, (2000) Conditional deletion of the Bcl-x gene from erythroid cells results in hemolytic anemia and profound splenomegaly. Development (Cambridge, England) 127, 4949-4958.
51. Mason KD, Carpinelli MR, Fletcher JI, Collinge JE, Hilton AA, Ellis S, Kelly PN, Ekert PG, Metcalf D, Roberts AW, et al,. (2007) Programmed anuclear cell death delimits platelet life span. Cell 128, 1173-1186.
52. Debrincat MA, Josefsson EC, James C, Henley KJ, Ellis S, Lebois M, Betterman KL, Lane RM, Rogers KL, White MJ, et al,. (2012) Mcl-1 and Bcl-x(L) coordinately regulate megakaryocyte survival. Blood 119, 5850-5858.
53. Motoyama N, Kimura T, Takahashi T, Watanabe T, &, Nakano T, (1999) bcl-x prevents apoptotic cell death of both primitive and definitive erythrocytes at the end of maturation. J Exp Med 189, 1691-1698.
54. Rucker EB 3rd, Dierisseau P, Wagner KU, Garrett L, Wynshaw-Boris A, Flaws JA, &, Hennighausen L, (2000) Bcl-x and Bax regulate mouse primordial germ cell survival and apoptosis during embryogenesis. Mol Endocrinol 14, 1038-1052.
55. Walton KD, Wagner KU, Rucker EB 3rd, Shillingford JM, Miyoshi K, &, Hennighausen L, (2001) Conditional deletion of the bcl-x gene from mouse mammary epithelium results in accelerated apoptosis during involution but does not compromise cell function during lactation. Mech Dev 109, 281-293.
56. Umeda J, Sano S, Kogawa K, Motoyama N, Yoshikawa K, Itami S, Kondoh G, Watanabe T, &, Takeda J, (2003) In vivo cooperation between Bcl-xL and the phosphoinositide 3-kinase-Akt signaling pathway for the protection of epidermal keratinocytes from apoptosis. FASEB J 17, 610-620.
57. Kim DJ, Kataoka K, Sano S, Connolly K, Kiguchi K, &, DiGiovanni J, (2009) Targeted disruption of Bcl-xL in mouse keratinocytes inhibits both UVB- and chemically induced skin carcinogenesis. Mol Carcinog 48, 873-885.
58. Takehara T, Tatsumi T, Suzuki T, Rucker EB 3rd, Hennighausen L, Jinushi M, Miyagi T, Kanazawa Y, &, Hayashi N, (2004) Hepatocyte-specific disruption of Bcl-xL leads to continuous hepatocyte apoptosis and liver fibrotic responses. Gastroenterology 127, 1189-1197.
59. Hikita H, Takehara T, Kodama T, Shimizu S, Hosui A, Miyagi T, Tatsumi T, Ishida H, Ohkawa K, Li W, et al,. (2009) BH3-only protein bid participates in the Bcl-2 network in healthy liver cells. Hepatology 50, 1972-1980.
60. Staversky RJ, Vitiello PF, Yee M, Callahan LM, Dean DA, &, O'Reilly MA, (2010) Epithelial ablation of Bcl-XL increases sensitivity to oxygen without disrupting lung development. Am J Respir Cell Mol Biol 43, 376-385.
61. Harder JM, Ding Q, Fernandes KA, Cherry JD, Gan L, &, Libby RT, (2012) BCL2L1 (BCL-X) promotes survival of adult and developing retinal ganglion cells. Mol Cell Neurosci 51, 53-59.
62. Savitt JM, Jang SS, Mu W, Dawson VL, &, Dawson TM, (2005) Bcl-x is required for proper development of the mouse substantia nigra. J Neurosci 25, 6721-6728.
63. Akhtar RS, Klocke BJ, Strasser A, &, Roth KA, (2008) Loss of BH3-only protein Bim inhibits apoptosis of hemopoietic cells in the fetal liver and male germ cells but not neuronal cells in bcl-x-deficient mice. J Histochem Cytochem 56, 921-927.
64. Perciavalle RM, Stewart DP, Koss B, Lynch J, Milasta S, Bathina M, Temirov J, Cleland MM, Pelletier S, Schuetz JD, et al,. (2012) Anti-apoptotic MCL-1 localizes to the mitochondrial matrix and couples mitochondrial fusion to respiration. Nat Cell Biol 14, 575-583.
65. Baumgartner F, Woess C, Pedit V, Tzankov A, Labi V, &, Villunger A, (2013) Minor cell-death defects but reduced tumor latency in mice lacking the BH3-only proteins Bad and Bmf. Oncogene 32, 621-630.
66. Nijhawan D, Fang M, Traer E, Zhong Q, Gao W, Du F, &, Wang X, (2003) Elimination of Mcl-1 is required for the initiation of apoptosis following ultraviolet irradiation. Genes Dev 17, 1475-1486.
67. Wertz IE, Kusam S, Lam C, Okamoto T, Sandoval W, Anderson DJ, Helgason E, Ernst JA, Eby M, Liu J, et al,. (2011) Sensitivity to antitubulin chemotherapeutics is regulated by MCL1 and FBW7. Nature 471, 110-114.
68. Fava LL, &, Villunger A, (2014) Stop competing, start talking!. EMBO J 33, 1849-1851.
69. Campbell KJ, Bath ML, Turner ML, Vandenberg CJ, Bouillet P, Metcalf D, Scott CL, &, Cory S, (2010) Elevated Mcl-1 perturbs lymphopoiesis, promotes transformation of hematopoietic stem/progenitor cells and enhances drug-resistance. Blood 116, 3197-3207.
70. Zhou P, Qian L, Bieszczad CK, Noelle R, Binder M, Levy NB, &, Craig RW, (1998) Mcl-1 in transgenic mice promotes survival in a spectrum of hematopoietic cell types and immortalization in the myeloid lineage. Blood 92, 3226-3239.
71. Zhou P, Levy NB, Xie H, Qian L, Lee CY, Gascoyne RD, &, Craig RW, (2001) MCL1 transgenic mice exhibit a high incidence of B-cell lymphoma manifested as a spectrum of histologic subtypes. Blood 97, 3902-3909.
72. Brunelle JK, Ryan J, Yecies D, Opferman JT, &, Letai A, (2009) MCL-1-dependent leukemia cells are more sensitive to chemotherapy than BCL-2-dependent counterparts. J Cell Biol 187, 429-442.
73. Opferman JT, Iwasaki H, Ong CC, Suh H, Mizuno S, Akashi K, &, Korsmeyer SJ, (2005) Obligate role of anti-apoptotic MCL-1 in the survival of hematopoietic stem cells. Science (New York, NY) 307, 1101-1104.
74. Steimer DA, Boyd K, Takeuchi O, Fisher JK, Zambetti GP, &, Opferman JT, (2009) Selective roles for antiapoptotic MCL-1 during granulocyte development and macrophage effector function. Blood 113, 2805-2815.
75. Dzhagalov I, St John A, &, He YW, (2007) The antiapoptotic protein Mcl-1 is essential for the survival of neutrophils but not macrophages. Blood 109, 1620-1626.
76. Opferman JT, Letai A, Beard C, Sorcinelli MD, Ong CC, &, Korsmeyer SJ, (2003) Development and maintenance of B and T lymphocytes requires antiapoptotic MCL-1. Nature 426, 671-676.
77. Tripathi P, Koss B, Opferman JT, &, Hildeman DA, (2013) Mcl-1 antagonizes Bax/Bak to promote effector CD4(+) and CD8(+) T-cell responses. Cell Death Differ 20, 998-1007.
78. Dunkle A, Dzhagalov I, &, He YW, (2010) Mcl-1 promotes survival of thymocytes by inhibition of Bak in a pathway separate from Bcl-2. Cell Death Differ 17, 994-1002.
79. Peperzak V, Vikstrom I, Walker J, Glaser SP, LePage M, Coquery CM, Erickson LD, Fairfax K, Mackay F, Strasser A, et al,. (2013) Mcl-1 is essential for the survival of plasma cells. Nat Immunol 14, 290-297.
80. Lilla JN, Chen CC, Mukai K, Benbarak MJ, Franco CB, Kalesnikoff J, Yu M, Tsai M, Piliponsky AM, &, Galli SJ, (2011) Reduced mast cell and basophil numbers and function in Cpa3-Cre; Mcl-1fl/fl mice. Blood 118, 6930-6938.
81. Weber A, Boger R, Vick B, Urbanik T, Haybaeck J, Zoller S, Teufel A, Krammer PH, Opferman JT, Galle PR, et al,. (2010) Hepatocyte-specific deletion of the antiapoptotic protein myeloid cell leukemia-1 triggers proliferation and hepatocarcinogenesis in mice. Hepatology 51, 1226-1236.
82. Vick B, Weber A, Urbanik T, Maass T, Teufel A, Krammer PH, Opferman JT, Schuchmann M, Galle PR, &, Schulze-Bergkamen H, (2009) Knockout of myeloid cell leukemia-1 induces liver damage and increases apoptosis susceptibility of murine hepatocytes. Hepatology 49, 627-636.
83. Kaufmann T, Jost PJ, Pellegrini M, Puthalakath H, Gugasyan R, Gerondakis S, Cretney E, Smyth MJ, Silke J, Hakem R, et al,. (2009) Fatal hepatitis mediated by tumor necrosis factor TNFalpha requires caspase-8 and involves the BH3-only proteins Bid and Bim. Immunity 30, 56-66.
84. Hikita H, Takehara T, Shimizu S, Kodama T, Li W, Miyagi T, Hosui A, Ishida H, Ohkawa K, Kanto T, et al,. (2009) Mcl-1 and Bcl-xL cooperatively maintain integrity of hepatocytes in developing and adult murine liver. Hepatology 50, 1217-1226.
85. Wang X, Bathina M, Lynch J, Koss B, Calabrese C, Frase S, Schuetz JD, Rehg JE, &, Opferman JT, (2013) Deletion of MCL-1 causes lethal cardiac failure and mitochondrial dysfunction. Genes Dev 27, 1351-1364.
86. Arbour N, Vanderluit JL, Le Grand JN, Jahani-Asl A, Ruzhynsky VA, Cheung EC, Kelly MA, MacKenzie AE, Park DS, Opferman JT, et al,. (2008) Mcl-1 is a key regulator of apoptosis during CNS development and after DNA damage. J Neurosci 28, 6068-6078.
87. Malone CD, Hasan SM, Roome RB, Xiong J, Furlong M, Opferman JT, &, Vanderluit JL, (2012) Mcl-1 regulates the survival of adult neural precursor cells. Mol Cell Neurosci 49, 439-447.
88. Germain M, Nguyen AP, Le Grand JN, Arbour N, Vanderluit JL, Park DS, Opferman JT, &, Slack RS, (2011) MCL-1 is a stress sensor that regulates autophagy in a developmentally regulated manner. EMBO J 30, 395-407.
89. Ottina E, Tischner D, Herold MJ, &, Villunger A, (2012) A1/Bfl-1 in leukocyte development and cell death. Exp Cell Res 318, 1291-1303.
90. Mandal M, Borowski C, Palomero T, Ferrando AA, Oberdoerffer P, Meng F, Ruiz-Vela A, Ciofani M, Zuniga-Pflucker JC, Screpanti I, et al,. (2005) The BCL2A1 gene as a pre-T cell receptor-induced regulator of thymocyte survival. J Exp Med 201, 603-614.
91. Verschelde C, Walzer T, Galia P, Biemont MC, Quemeneur L, Revillard JP, Marvel J, &, Bonnefoy-Berard N, (2003) A1/Bfl-1 expression is restricted to TCR engagement in T lymphocytes. Cell Death Differ 10, 1059-1067.
92. Tomayko MM, Punt JA, Bolcavage JM, Levy SL, Allman DM, &, Cancro MP, (1999) Expression of the Bcl-2 family member A1 is developmentally regulated in T cells. Int Immunol 11, 1753-1761.
93. Trescol-Biemont MC, Verschelde C, Cottalorda A, &, Bonnefoy-Berard N, (2004) Regulation of A1/Bfl-1 expression in peripheral splenic B cells. Biochimie 86, 287-294.
94. Haq R, Yokoyama S, Hawryluk EB, Jonsson GB, Frederick DT, McHenry K, Porter D, Tran TN, Love KT, Langer R, et al,. (2013) BCL2A1 is a lineage-specific antiapoptotic melanoma oncogene that confers resistance to BRAF inhibition. Proc Natl Acad Sci USA 110, 4321-4326.
95. Vogler M, (2011) BCL2A1: the underdog in the BCL2 family. Cell Death Differ 19, 67-74.
96. Herold MJ, Zeitz J, Pelzer C, Kraus C, Peters A, Wohlleben G, &, Berberich I, (2006) The stability and anti-apoptotic function of A1 are controlled by its C terminus. J Biol Chem 281, 13663-13671.
97. Chuang PI, Morefield S, Liu CY, Chen S, Harlan JM, &, Willerford DM, (2002) Perturbation of B-cell development in mice overexpressing the Bcl-2 homolog A1. Blood 99, 3350-3359.
98. Gonzalez J, Orlofsky A, &, Prystowsky MB, (2003) A1 is a growth-permissive antiapoptotic factor mediating postactivation survival in T cells. Blood 101, 2679-2685.
99. Xiang Z, Ahmed AA, Moller C, Nakayama K, Hatakeyama S, &, Nilsson G, (2001) Essential role of the prosurvival bcl-2 homologue A1 in mast cell survival after allergic activation. J Exp Med 194, 1561-1569.
100. Kausalya S, Somogyi R, Orlofsky A, &, Prystowsky MB, (2001) Requirement of A1-a for bacillus Calmette-Guerin-mediated protection of macrophages against nitric oxide-induced apoptosis. J Immunol 166, 4721-4727.
101. Ottina E, Grespi F, Tischner D, Soratroi C, Geley S, Ploner A, Reichardt HM, Villunger A, &, Herold MJ, (2012) Targeting antiapoptotic A1/Bfl-1 by in vivo RNAi reveals multiple roles in leukocyte development in mice. Blood 119, 6032-6042.
102. Ottina E, Lyberg K, Sochalska M, Villunger A, &, Nilsson G, (2015) Knockdown of the anti-apoptotic Bcl-2-family member A1/Bfl-1 protects mice from anaphylaxis. J Immunology pii: 1400637. [Epub ahead of print]
103. Anderson MA, Huang D, &, Roberts A, (2014) Targeting BCL2 for the treatment of lymphoid malignancies. Semin Hematol 51, 219-227.
104. Lessene G, Czabotar PE, Sleebs BE, Zobel K, Lowes KN, Adams JM, Baell JB, Colman PM, Deshayes K, Fairbrother WJ, et al,. (2013) Structure-guided design of a selective BCL-X(L) inhibitor. Nat Chem Biol 9, 390-397.
105. Tse C, Shoemaker AR, Adickes J, Anderson MG, Chen J, Jin S, Johnson EF, Marsh KC, Mitten MJ, Nimmer P, et al,. (2008) ABT-263: a potent and orally bioavailable Bcl-2 family inhibitor. Cancer Res 68, 3421-3428.
106. Souers AJ, Leverson JD, Boghaert ER, Ackler SL, Catron ND, Chen J, Dayton BD, Ding H, Enschede SH, Fairbrother WJ, et al,. (2013) ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets. Nat Med 19, 202-208.
107. Oltersdorf T, Elmore SW, Shoemaker AR, Armstrong RC, Augeri DJ, Belli BA, Bruncko M, Deckwerth TL, Dinges J, Hajduk PJ, et al,. (2005) An inhibitor of Bcl-2 family proteins induces regression of solid tumours. Nature 435, 677-681.
108. Wilson WH, O'Connor OA, Czuczman MS, LaCasce AS, Gerecitano JF, Leonard JP, Tulpule A, Dunleavy K, Xiong H, Chiu YL, et al,. (2010) Navitoclax, a targeted high-affinity inhibitor of BCL-2, in lymphoid malignancies: a phase 1 dose-escalation study of safety, pharmacokinetics, pharmacodynamics, and antitumour activity. Lancet Oncol 11, 1149-1159.
109. Vlahovic G, Karantza V, Wang D, Cosgrove D, Rudersdorf N, Yang J, Xiong H, Busman T, &, Mabry M, (2014) A phase I safety and pharmacokinetic study of ABT-263 in combination with carboplatin/paclitaxel in the treatment of patients with solid tumors. Invest New Drugs 32, 976-984.
110. Cleary JM, Lima CM, Hurwitz HI, Montero AJ, Franklin C, Yang J, Graham A, Busman T, Mabry M, Holen K, et al,. (2014) A phase I clinical trial of navitoclax, a targeted high-affinity Bcl-2 family inhibitor, in combination with gemcitabine in patients with solid tumors. Invest New Drugs 32, 937-945.
111. Iwasawa M, Miyazaki T, Nagase Y, Akiyama T, Kadono Y, Nakamura M, Oshima Y, Yasui T, Matsumoto T, Nakamura T, et al,. (2009) The antiapoptotic protein Bcl-xL negatively regulates the bone-resorbing activity of osteoclasts in mice. J Clin Investig 119, 3149-3159.
112. Kelly GL, Grabow S, Glaser SP, Fitzsimmons L, Aubrey BJ, Okamoto T, Valente LJ, Robati M, Tai L, Fairlie WD, et al,. (2014) Targeting of MCL-1 kills MYC-driven mouse and human lymphomas even when they bear mutations in p53. Genes Dev 28, 58-70.
113. Koss B, Morrison J, Perciavalle RM, Singh H, Rehg JE, Williams RT, &, Opferman JT, (2013) Requirement for antiapoptotic MCL-1 in the survival of BCR-ABL B-lineage acute lymphoblastic leukemia. Blood 122, 1587-1598.
114. Xiang Z, Luo H, Payton JE, Cain J, Ley TJ, Opferman JT, &, Tomasson MH, (2010) Mcl1 haploinsufficiency protects mice from Myc-induced acute myeloid leukemia. J Clin Investig 120, 2109-2118.
115. Yecies D, Carlson NE, Deng J, &, Letai A, (2011) Acquired resistance to ABT-737 in lymphoma cells that up-regulate MCL-1 and BFL-1. Blood 115, 3304-3313.
116. Vogler M, Butterworth M, Majid A, Walewska RJ, Sun XM, Dyer MJ, &, Cohen GM, (2009) Concurrent up-regulation of BCL-XL and BCL2A1 induces approximately 1000-fold resistance to ABT-737 in chronic lymphocytic leukemia. Blood 113, 4403-4413.
117. Vaillant F, Merino D, Lee L, Breslin K, Pal B, Ritchie ME, Smyth GK, Christie M, Phillipson LJ, Burns CJ, et al,. (2013) Targeting BCL-2 with the BH3 mimetic ABT-199 in estrogen receptor-positive breast cancer. Cancer Cell 24, 120-129.
118. Tischner D, Woess C, Ottina E, &, Villunger A, (2010) Bcl-2-regulated cell death signalling in the prevention of autoimmunity. Cell Death Dis 1, e48.
119. Carrington EM, Vikstrom IB, Light A, Sutherland RM, Londrigan SL, Mason KD, Huang DC, Lew AM, &, Tarlinton DM, (2010) BH3 mimetics antagonizing restricted prosurvival Bcl-2 proteins represent another class of selective immune modulatory drugs. Proc Natl Acad Sci USA 107, 10967-10971.
120. Josefsson EC, James C, Henley KJ, Debrincat MA, Rogers KL, Dowling MR, White MJ, Kruse EA, Lane RM, Ellis S, et al,. (2011) Megakaryocytes possess a functional intrinsic apoptosis pathway that must be restrained to survive and produce platelets. J Exp Med 208, 2017-2031.